BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interim Data Review Conferen
Click here to view original post
News
How Can Employers Help When Workers Struggle With Substance Use?
It’s no secret that Coloradans are struggling with substance use and mental health issues. Click here to view original post
News
What Parents Need to Know about Teens and Sextortion
It’s become an all-too-common story. A teenage boy shares an explicit photo with a girl he’s been chatting with online. Minutes later, an unknown person sends a threatening message: Pay a large sum of money, […]
News
Health care technology company hires within for new CEO
Connexall offers integration and communication platform used by major health systems in the U.S. and Canada. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
